| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/LIV.12616 |
| P698 | PubMed publication ID | 24905624 |
| P50 | author | Sonja K. Olsen | Q79190010 |
| P2093 | author name string | Robert S Brown | |
| Kirti Shetty | |||
| Elizabeth C Verna | |||
| Lorna M Dove | |||
| Alyson N Fox | |||
| Kimiknu Mentore | |||
| Nicole Terry | |||
| Thresiamma Lukose | |||
| P2860 | cites work | Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. | Q45722053 |
| Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. | Q46122164 | ||
| Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. | Q47678268 | ||
| Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. | Q50574695 | ||
| Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 | ||
| Telaprevir for retreatment of HCV infection | Q29619799 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation | Q30413350 | ||
| A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation | Q33342063 | ||
| Telaprevir for previously treated chronic HCV infection | Q34109057 | ||
| Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection | Q34607097 | ||
| A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy | Q35384561 | ||
| Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience | Q42272968 | ||
| Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial | Q42943536 | ||
| Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy | Q42985235 | ||
| Telaprevir and peginterferon with or without ribavirin for chronic HCV infection | Q42987218 | ||
| Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy | Q42993823 | ||
| Liver transplantation in the United States, 1999-2008. | Q43499740 | ||
| Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. | Q44847210 | ||
| P433 | issue | 2 | |
| P921 | main subject | virology | Q7215 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 510-517 | |
| P577 | publication date | 2014-07-10 | |
| P1433 | published in | Liver International | Q15765078 |
| P1476 | title | High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy | |
| P478 | volume | 35 |
| Q26782017 | Impact of new treatment options for hepatitis C virus infection in liver transplantation |
| Q26773224 | Liver transplantation for viral hepatitis in 2015 |
| Q38500364 | Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C. |
| Q30250096 | The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma |
| Q35790393 | Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? |
| Q38431523 | Treatment of hepatitis C in difficult-to-treat patients |
| Q42980035 | Universal Hepatitis C Eradication Prior to Liver Transplantation: We Can Do It, but Should We? |
Search more.